Before You Book the Freight: A Pre-Shipment FDA Readiness Checklist for Pharmaceutical Importers
In the first week of September 2026, FDA refreshed three pharmaceutical import alerts: Import Alert 66-40, covering drugs from firms that have not met GMP requirements; Import Alert 99-34, covering drugs and medical devices from firms without valid registration or listing; and Import Alert 66-41, covering unapproved new drugs promoted in the United States. These were updates to existing enforcement mechanisms, not newly created rules. FDA’s import alert database is refreshed continuously, and firms and products are added and removed as compliance circumstances change.
Routine as these updates are, they carry a consistent and important lesson for any company importing pharmaceutical or medical product: import readiness begins before transportation. The most consequential compliance work happens before the freight is ever booked, and the parties who move the cargo, the freight forwarder, the customs broker, and the warehouse, should never be the first to discover that a shipment was inadmissible.
The single most expensive mistake in pharmaceutical importing is discovering an admissibility problem after the product has arrived, when the only options left are costly and slow. The solution is to verify readiness before booking the freight, when problems can still be prevented rather than managed.
Why Pre-Shipment Readiness Matters So Much
When an admissibility problem is caught before a shipment departs, it is a scheduling inconvenience. The company resolves the issue, then ships. When the same problem is caught after the product arrives at a U.S. port, it becomes an operational crisis with a cascade of consequences that compound by the day.
Consider what actually happens when temperature-sensitive pharmaceutical product arrives and is found inadmissible, because the manufacturer is on an import alert, the facility registration is invalid, the product listing is wrong, or FDA otherwise considers the product inadmissible:
- Controlled storage: the product must be placed into validated conditions while the issue is worked, if such storage can even be arranged in time
- Carrier charges and demurrage: detention and demurrage costs accrue daily while the shipment sits
- QA escalation: the company’s quality team is pulled into an urgent, unplanned compliance response
- Documentation retrieval: the company scrambles to assemble records from the foreign manufacturer, often across time zones and language barriers
- Potential export or destruction: if the issue cannot be resolved, the product must be re-exported or destroyed, generally at the importer’s expense
- Reduced validated transit life: every hour of delay consumes the product’s remaining validated shelf life, and for a temperature-sensitive biologic, that clock does not stop
The Core Reality: A freight forwarder, customs broker, or warehouse cannot fix a registration deficiency, a listing error, or an import alert designation after the product reaches the border. These are pre-shipment problems, and they have pre-shipment solutions. Once the cargo has arrived, the problem is no longer preventable. It is only manageable, at cost.
The Pre-Shipment FDA Readiness Checklist
The following ten checkpoints should be confirmed before a pharmaceutical or medical product shipment is booked for transport. Each one addresses a specific, common cause of detention or refusal, and each one is far easier to resolve before the freight moves than after it arrives.
| # | Checkpoint | What To COnfirm Before Booking |
|---|---|---|
| 1 | Manufacturer identity | Confirm who actually manufactures the product, not just the name on the invoice |
| 2 | Manufacturing-site address | Verify the specific facility where the product is made |
| 3 | Establishment registration | Confirm the facility’s FDA registration is current and valid |
| 4 | Product listing | Confirm the specific product is correctly listed with FDA |
| 5 | Import-alert status | Check whether the firm or product appears on an active import alert |
| 6 | Intended use | Confirm the declared use, which can affect admissibility and classification |
| 7 | FDA product information | Confirm required FDA product codes and Affirmation of Compliance data |
| 8 | Importer-of-record data | Verify the IOR information and its standing with CBP |
| 9 | Customs classification | Confirm the correct HTS classification for the product |
| 10 | Contingency plan | Define what happens operationally if clearance is delayed or the entry is held |
The Checkpoints That Cause the Most Trouble
All ten checkpoints matter, but a few deserve particular attention because they are the most common and the most preventable causes of holds.
Manufacturer Identity and Site Address (Checkpoints 1 and 2)
A surprising number of holds trace back to confusion about who actually manufactures a product and where. The name on a commercial invoice may be a distributor, a trading company, or a corporate parent rather than the actual manufacturing establishment. FDA’s admissibility determination depends on the real manufacturing facility. Confirming manufacturer identity and the specific site address is the foundation that the registration and listing checks build on.
Establishment Registration and Product Listing (Checkpoints 3 and 4)
These two are the most common preventable causes of detention, and they are distinct. A facility can be registered while a specific product is not correctly listed. Both must be current and valid, and both should be verified independently against FDA records rather than taken on the supplier’s assurance. Registration and listing status can change, so a check performed months ago at initial qualification is not a substitute for verification before a specific shipment.
Import-Alert Status (Checkpoint 5)
Because FDA’s import alert database is refreshed continuously, a manufacturer or product that was clear when a supplier relationship began can be added to an alert later. Checking current import alert status before shipment, for the specific manufacturer and product, is the only way to confirm the shipment will not be subject to detention without physical examination on arrival.
The Contingency Plan (Checkpoint 10)
Even with thorough verification, delays can happen for reasons outside the importer’s control. The final checkpoint is not a verification but a plan: if this shipment is delayed or held at the border, what happens? Where will the product be stored under validated conditions? Who is notified? Who has the authority to act? For temperature-sensitive product, having this plan defined in advance is the difference between a managed delay and a product loss.
Where Logistics and Compliance Meet
This checklist sits precisely at the intersection of customs compliance and logistics, which is exactly why it belongs in the pre-shipment conversation rather than being treated as a separate regulatory exercise. The customs broker who will file the entry needs the manufacturer, registration, listing, and classification information to be correct. The warehouse that will receive the product needs to know its temperature requirements and its quality status. The freight plan depends on the product actually being admissible when it arrives.
When these functions are integrated, the pre-shipment readiness check becomes a natural part of the logistics process rather than a separate step that may or may not happen. A logistics partner with in-house licensed customs brokerage can verify admissibility as part of planning the shipment, catching problems while they are still preventable. That integration is the practical mechanism that turns import readiness from a hope into a process.
Pre-Shipment Readiness
Euro-American Worldwide Logistics operates a licensed in-house U.S. Customs Brokerage integrated with cGMP-compliant warehousing and international freight forwarding. For pharmaceutical and medical device clients, our brokerage team verifies establishment registration, product listing, and import alert status as part of pre-shipment compliance review, before the freight is booked, not after the product is held at the border.
For clients working with new suppliers or shipping after a gap in activity, we can perform this readiness verification as part of shipment planning, and because our customs brokerage and cGMP warehouse operate as one team, we have both the compliance visibility to catch problems early and the validated storage to protect product if a delay occurs despite everyone’s best efforts.
If you would like to review your pre-shipment readiness process, or have a shipment you want verified before booking, contact our team.
This article references FDA import alert updates from the first week of September 2026, including Import Alerts 66-40, 99-34, and 66-41. Import alert status should be verified directly against FDA’s current records before each shipment. This article is informational and not legal advice.
